Neuralgia News and Research

RSS

Neuralgia is pain in one or more nerves that occurs without stimulation of pain receptor (nociceptor) cells. Neuralgia pain is produced by a change in neurological structure or function rather than by the excitation of pain receptors that causes nociceptive pain.

Using peripheral nerve blocks to treat facial pain may produce long-term pain relief

A new study has shown that use of peripheral nerve blocks in the treatment of Trigeminal Neuralgia may produce long-term pain relief.

14 Aug 2018

Depression, antidepressant use linked with higher risk of venous thromboembolism

In the first review of its kind, new research has found that depression and the use of antidepressants are each associated with an increased risk of venous thromboembolism.

24 Jul 2018

Electronic system to speed up facial pain diagnosis may improve quality of life and save money

Patients with persistent facial pain are costing the economy more than £3,000 each per year, new research has revealed.

17 Jul 2018

Fredrick Junn, M.D. recognized as Pinnacle Professional Member in the Medical field

Fredrick Junn, M.D., is recognized by Continental Who's Who as a Pinnacle Professional Member in the Medical field.

28 Apr 2018

Adults skipping vaccines may miss out on effective new shingles shot

Federal officials have recommended a new vaccine that is more effective than an earlier version at protecting older adults against the painful rash called shingles. But persuading many adults to get this and other recommended vaccines continues to be an uphill battle, physicians and vaccine experts say.

20 Mar 2018

Shot may help reduce risk of shingles

Anyone who has had chickenpox or the chickenpox vaccine is at risk for the painful skin condition herpes zoster, more commonly known as shingles. Both diseases are caused by the varicella-zoster virus, which stays in the body after chickenpox clears and may reactivate later in life.

18 Feb 2018

CDC recommends new vaccine for shingles

Last month a U.S. Food and Drug Administration (FDA) advisory panel had voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline’s Shingrix.

25 Oct 2017

New shingles vaccine gets FDA panel votes

On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline’s Shingrix is on its way to FDA approval.

14 Sep 2017

Research reveals underlying reason for intense pain in patients with shingles

Chickenpox is a typical childhood illness. In most cases, it is benign, and the symptoms disappear within ten days. However, its causative agent, Varicella zoster virus (VZV), remains in the organism forever. In some cases, the virus can be reactivated years later, causing a different disease known as herpes zoster, or shingles.

24 Aug 2017

Shingles raises the risk for heart attack and stroke

Persons who have had chicken pox are prone to develop shingles with the Herpes zoster virus that lays dormant within them. A new study has shown that getting shingles - a painful skin condition caused by the virus could also raise the risk of heart disease such as heart attacks and strokes in individuals. The study was published in the Journal of the American College of Cardiology.

5 Jul 2017

Early radiosurgery could make big difference to lives of patients with trigeminal neuralgia

Doctors should consider radiosurgery earlier for patients with severe facial pain, according to a new study in the International Journal of Radiation Oncology Biology Physics (the "Red Journal") - the official journal of the American Society for Radiation Oncology.

3 Jul 2017

Novel substance can effectively inhibit chronic nerve pain, study shows

Trigeminal neuralgia is characterized by sharp, lancinating pain in the teeth or facial area. The standard treatment for this chronic nerve pain can cause burdening side effects.

20 Feb 2017

Neurologists identify cause of immune-mediated neuropathies

Würzburg neurologists have discovered an antibody that is involved in triggering certain forms of neuropathies. This discovery also allowed them to show a way to treat these diseases successfully.

3 Aug 2016

FDA approves non-alcoholic Docetaxel Injection

Teikoku Pharma USA, Inc. announced today that the U.S. Food and Drug Administration has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

29 Dec 2015

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research Inc., a life sciences company with growing revenues and a diverse portfolio of topical products, today announced the results of its investigational Phase 2 clinical trial of WF10 (Trial) for the treatment of allergic rhinitis.

21 Dec 2015

Shingles vaccine can help protect elderly patients with end-stage renal disease

Elderly patients with end-stage renal disease (ESRD) who received the shingles vaccine were half as likely to develop shingles compared to those who were not vaccinated. The new study from Kaiser Permanente, published in Clinical Infectious Diseases, also found the best protection against shingles was achieved when patients received the vaccination shortly after beginning dialysis.

16 Dec 2015

Delaying stereotactic radiosurgery worsens trigeminal neuralgia pain outcomes

Stereotactic radiosurgery, as a first surgical procedure for medically refractory trigeminal neuralgia, should be performed within 3 years of pain onset to achieve the best results, researchers recommend.

25 Nov 2015

Psychiatric disorders may follow trigeminal neuralgia

Patients with trigeminal neuralgia have an increased risk of later developing certain psychiatric disorders, a population-based study suggests.

21 Aug 2015

Study: Chickenpox vaccination increases incidence of shingles in younger adults

Vaccinating one-year-olds against chickenpox could temporarily nearly double the incidence of shingles in the wider population, but in younger adults than previously thought.

12 Aug 2015

Mylan announces launch of Lidocaine Patch 5% in the U.S.

Mylan N.V. today announced the U.S. launch of its Lidocaine Patch 5%, which is the generic version of Endo Pharmaceutical's Lidoderm. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for relief of pain associated with post-herpetic neuralgia.

10 Aug 2015